Advanz Pharma has signed an agreement with Intercept Pharmaceuticals to acquire most of the its subsidiaries and non-US operations.
UK-headquartered pharma company, Advanz Pharma, has announced in a May 5, 2022 press release that it has signed an agreement with US biopharma company, Intercept Pharmaceuticals, to acquire most of the company’s subsidiaries and non-US operations.
According to the press release, through the agreement, Advanz Pharma will acquire Intercept’s operations in Europe, Canada, and all other non-US markets, and will include the ex-US rights for the commercialization of Ocaliva (obeticholic acid)—an orphan drug for the treatment of primary biliary cholangitis (PBC). Additionally, as per the terms of the agreement Advanz Pharma will gain the rights to commercialize obeticholic acid in non-alcoholic steatohepatitis (outside of the United States), in exchange for royalty payments on any future net sales.
“This acquisition is transformational for Advanz Pharma,” said Steffen Wagner, CEO at Advanz Pharma, in the press release. “Acquiring this high-quality rare disease business outside of the US grows our position as a partner of choice for specialty and hospital pharmaceuticals in Europe, and we are thrilled to welcome Intercept’s dedicated and experienced team, which will bring additional capabilities to us for the benefit of patients.”
“We look forward to building on this transaction as we continue to strengthen our platform for future acquisitions and in-licensing agreements to drive growth, especially in the areas of gastroenterology and hepatology as well as more broadly in rare diseases,” added Susanna El-Armale, chief corporate development officer at Advanz Pharma, in the press release.
Under the financial terms of the agreement, Advanz Pharma is expected to pay Intercept and upfront consideration of $405 million, in addition to $45 million as contingency once an extension of pediatric orphan exclusivity is received in Europe.
Source: Advanz Pharma
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.